Inevitable competition between multinational and domestic pharmaceutical companies in the KRW 400 billion NSAIDs market

In the KRW 400 billion NSAIDs (non-steroidal anti-inflammatory drugs) market, the ‘2^nd’ severe competition is expected among domestic and multinational pharmaceutical companies. .

First and foremost, among domestic pharmaceutical companies, Daewon Pharm has started the phenomenon by opening the launching symposium for the first domestic NSAID, the improved drug of ‘Pelubi Tab,’ ‘Pelubi SR Tab,...